Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nano Terra has granted Kadmon Pharmaceuticals a perpetual, worldwide exclusive license to novel, clinical-stage product candidates SLx-2119, SLx-4090 and SLx-2101 as well as rights to drug discovery platform - Pharmacomer Technology.
Subscribe to our email newsletter
The product candidates are currently in early- to mid-stage clinical development for a variety of diseases.
They target several novel pathways of disease by inhibiting the activity of specific enzymes such as ROCK2 (Rho-associated coiled-coiled kinase 2), the target of SLx-2119; MTP (enterocytic microsomal triglyceride transfer protein), the target of SLx-4090; and PDE5 (phosphodiesterase 5), the target of SLx-2101.
Under the agreement, the licensed products and the technology will be transferred to a newly formed joint venture, NT Life Sciences, jointly owned by Kadmon and Nano Terra.
Kadmon Pharma chairman and CEO Samuel Waksal said this transaction brings to Kadmon remarkably well-developed clinical compounds targeting important pathways of disease as well as a powerful discovery engine, both having benefited from substantial investment to date.
The product candidates and Pharmacomer Technology platform were originally developed by Surface Logix, a company founded by Harvard chemist Professor George Whitesides, which is recently acquired by Nano Terra.